Postherpetic Neuralgia: When Shingles Pain Refuses to Leave
Postherpetic neuralgia is shingles' documented afterlife — nerve pain that outstays the rash. The allodynia signature, the treatment layers, the fade horizon, and the vaccine paragraph survivors insist on.
· By The Editors
The press does not currently name a clinical reviewer of record. Read about contributor roles and the review process before using health information. Editors & Contributors.
Shingles has a famous rash and an infamous afterlife. When the blisters heal but the pain stays — burning, stabbing, or skin so sensitized that a shirt sleeve becomes unbearable — it has crossed into postherpetic neuralgia, the complication the research literature calls shingles' most common serious consequence and the reason clinicians push vaccination so hard. Sufferers describe a strange informational cliff: abundant advice about the rash, near-silence about the months or years that can follow it.
Who it strikes and why
The virus damages the very nerves it traveled, and the literature's risk factors are consistent: age above all — risk climbs steeply past sixty — plus severe rashes, severe acute pain, and delayed antiviral treatment. The mechanism is nerve injury, which explains the character of the pain: burning and electric rather than sore, with allodynia — pain from light touch — as its signature cruelty. Patients describe cutting tags from clothing, dreading wind on skin, and the exhaustion of pain that rides every brush of fabric.
What the evidence offers
Honest framing first: established postherpetic neuralgia is managed more often than cured, and early treatment of shingles itself — antivirals within seventy-two hours of the rash — is documented to matter for what follows. For the neuralgia: first-line neuropathic medications; lidocaine patches worn over the painful territory, which many describe as the difference between wearing clothes and not; high-concentration capsaicin patch treatments applied in clinic; layered approaches for stubborn cases; and time — the literature and testimony agree that many cases slowly fade over months to a couple of years, a horizon worth knowing on the bad days.
The prevention paragraph patients insist on
The recombinant shingles vaccine is strikingly effective at preventing both shingles and this aftermath, and sufferers are its fiercest evangelists — the recurring line in accounts addressed to younger friends is some version of “get the shot; you do not want to learn this condition's name the way I did.” Our companion piece on shingles and the vaccine covers that decision.
Fifty first-person accounts of infections and their long shadows live on our Infectious Diseases & Recovery shelf; start with our reading guide.
Sources and further reading
- Post-herpetic neuralgia. NHS, reviewed February 2025.
- Shingles Vaccination. Centers for Disease Control and Prevention, August 2025.
- A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain, 2016.
- Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database of Systematic Reviews, 2014.
Companion reading, not medical advice. A new shingles rash is a same-week medical matter — and lasting pain after one deserves proper neuropathic treatment.
The Reading Room publishes personal stories and editorial notes from our press. Everything here is companion reading — never medical advice, diagnosis, or treatment. For guidance about your own health, please speak with a qualified clinician. Read how we collect and edit patient testimony in our Editorial Standards, or meet the editors on our Editors & Contributors page.
If this piece was useful, the volumes below hold fifty full-length accounts from people who have been through it — the part an article can only summarise.
